.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Baxter
Johnson and Johnson
Chubb
Fish and Richardson
Deloitte
Queensland Health
Healthtrust
Novartis
Daiichi Sankyo

Generated: November 21, 2017

DrugPatentWatch Database Preview

Symplmed Pharms Llc Company Profile

« Back to Dashboard

What is the competitive landscape for SYMPLMED PHARMS LLC, and what generic alternatives to SYMPLMED PHARMS LLC drugs are available?

SYMPLMED PHARMS LLC has two approved drugs.

There are two US patents protecting SYMPLMED PHARMS LLC drugs on SYMPLMED PHARMS LLC drugs in the past three years.

There are sixty-seven patent family members on SYMPLMED PHARMS LLC drugs in thirty-nine countries and sixteen supplementary protection certificates in eight countries.

Summary for Symplmed Pharms Llc

International Patents:67
US Patents:2
Tradenames:2
Ingredients:2
NDAs:2
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Symplmed Pharms Llc
PRESTALIA
amlodipine besylate; perindopril arginine
TABLET;ORAL205003-003Jan 21, 2015RXYesYes► Subscribe► SubscribeYY ► Subscribe
Symplmed Pharms Llc
PRESTALIA
amlodipine besylate; perindopril arginine
TABLET;ORAL205003-001Jan 21, 2015RXYesNo► Subscribe► SubscribeYY ► Subscribe
Symplmed Pharms Llc
PRESTALIA
amlodipine besylate; perindopril arginine
TABLET;ORAL205003-003Jan 21, 2015RXYesYes► Subscribe► SubscribeYY ► Subscribe
Symplmed Pharms Llc
PRESTALIA
amlodipine besylate; perindopril arginine
TABLET;ORAL205003-002Jan 21, 2015RXYesNo► Subscribe► SubscribeYY ► Subscribe
Symplmed Pharms Llc
ACEON
perindopril erbumine
TABLET;ORAL020184-001Dec 30, 1993DISCNYesNo► Subscribe► Subscribe► Subscribe
Symplmed Pharms Llc
PRESTALIA
amlodipine besylate; perindopril arginine
TABLET;ORAL205003-001Jan 21, 2015RXYesNo► Subscribe► Subscribe► Subscribe
Symplmed Pharms Llc
PRESTALIA
amlodipine besylate; perindopril arginine
TABLET;ORAL205003-002Jan 21, 2015RXYesNo► Subscribe► SubscribeYY ► Subscribe
Symplmed Pharms Llc
ACEON
perindopril erbumine
TABLET;ORAL020184-003Dec 30, 1993DISCNYesNo► Subscribe► Subscribe► Subscribe
Symplmed Pharms Llc
ACEON
perindopril erbumine
TABLET;ORAL020184-002Dec 30, 1993DISCNYesNo► Subscribe► Subscribe► Subscribe
Symplmed Pharms Llc
PRESTALIA
amlodipine besylate; perindopril arginine
TABLET;ORAL205003-002Jan 21, 2015RXYesNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Symplmed Pharms Llc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Symplmed Pharms Llc
ACEON
perindopril erbumine
TABLET;ORAL020184-001Dec 30, 1993► Subscribe► Subscribe
Symplmed Pharms Llc
ACEON
perindopril erbumine
TABLET;ORAL020184-002Dec 30, 1993► Subscribe► Subscribe
Symplmed Pharms Llc
ACEON
perindopril erbumine
TABLET;ORAL020184-003Dec 30, 1993► Subscribe► Subscribe
Symplmed Pharms Llc
ACEON
perindopril erbumine
TABLET;ORAL020184-003Dec 30, 1993► Subscribe► Subscribe
Symplmed Pharms Llc
ACEON
perindopril erbumine
TABLET;ORAL020184-002Dec 30, 1993► Subscribe► Subscribe
Symplmed Pharms Llc
ACEON
perindopril erbumine
TABLET;ORAL020184-001Dec 30, 1993► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for SYMPLMED PHARMS LLC drugs

Drugname Dosage Strength Tradename Submissiondate
perindopril arginine and amlodipine
Tablets3.5 mg/2.5 mg, 7 mg/5 mg and 14 mg/10 mg
PRESTALIA
11/4/2016
perindopril erbumine
Tablets2 mg, 4 mg and 8 mg
ACEON
6/6/2006

International Patent Family for Symplmed Pharms Llc Drugs

Country Document Number Estimated Expiration
European Patent Office1354873► Subscribe
Ukraine89905► Subscribe
Poland359321► Subscribe
China1451656► Subscribe
HungaryE027898► Subscribe
Georgia, Republic ofP20125433► Subscribe
Malaysia151035► Subscribe
Brazil0300709► Subscribe
South Africa200301395► Subscribe
Argentina039428► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Symplmed Pharms Llc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2011 00026Denmark► SubscribePRODUCT NAME: A COMBINATION OF OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE; NAT. REG. NO/DATE: 46260-46269 (DK) 20110323; FIRST REG. NO/DATE: DE 79810.00.00 20101216
00445Netherlands► SubscribePRODUCT NAME: VALSARTAN, AMLODIPINE EN HYDROCHLOORTHIAZIDE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; REGISTRATION NO/DATE: EU/1/09/569/001-060 20091016
00375Netherlands► SubscribePRODUCT NAME: COMBINATIE VAN OLMESARTAN MEDOXOMIL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT EN AMLODIPINEBESILAAT; REGISTRATION NO/DATE: RVG100984, RVG100986-87, RVG100989-91, RVG100993-95 20080819
0625Netherlands► SubscribePRODUCT NAME: COMBINATIE BEVATTENDE ALISKIREN, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, EN AMLODIPINE, OF EEN FARMACEUATISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/11/686/001-056 20110414
C/GB11/010United Kingdom► SubscribePRODUCT NAME: THE COMBINATION OF A) TELMISARTAN, OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALTS, AND B) AMLODIPINE, OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALTS, ESPECIALLY AMLODIPINE BESYLATE; REGISTERED: UK EU/1/10/648/001 20101007; UK EU/1/10/648/002 20101007; UK EU/1/10/648/003 20101007; UK EU/1/10/648/004 20101007; UK EU/1/10/648/005 20101007; UK EU/1/10/648/006 20101007; UK EU/1/10/648/007 20101007; UK EU/1/10/648/008 20101007; UK EU/1/10/648/009 20101007; UK EU/1/10/648/010 20101007; UK EU/1/10/648/011 20101007; UK EU/1/10/648/012 20101007; UK EU/1/10/648/013 20101007; UK EU/1/10/648/014 20101007; UK EU/1/10/648/015 20101007; UK EU/1/10/648/016 20101007; UK
00528Netherlands► SubscribePRODUCT NAME: COMBINATIE VAN ALISKIREN OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, AMLODIPINE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN HYDROCHLOORTHIAZIDE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; NATL. REGISTRATION NO/DATE: EU/1/11/730/001-060 20111122; FIRST REGISTRATION: CH 61678 01-05 20110705
315Luxembourg► SubscribePRODUCT NAME: COMBINAISON COMPRENANT ALISKIREN,OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE,ET AMLODIPINE,OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE
C0033France► SubscribePRODUCT NAME: ALISKIRENE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE E CELUI-CI, AMLODIPINE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, ET HYDROCHLOROTHIAZIDE OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; NAT. REGISTRATION NO/DATE: EU/1/11/730/001 20111122; FIRST REGISTRATION: 6167801 20110705
07C/043Belgium► SubscribePRODUCT NAME: AMLODIPINE ET VALSARTAN; NATL. REGISTRATION NO/DATE: EU/1/06/370/001 20070118; FIRST REGISTRATION: CH 57771 20061222
00478Netherlands► SubscribePRODUCT NAME: TELMISARTAN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN AMLODIPINE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER AMLODIPINEBESILAAT; REGISTRATION NO/DATE: EU/1/10/648/001-028 20101007
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Merck
Dow
Fish and Richardson
Fuji
Argus Health
Express Scripts
Mallinckrodt
Covington
Baxter
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot